Screening/Prevention
Women Share Breast and Ovarian Cancer Testing Results with Family Members
(04/25/2008)
Women who undergo testing for genetic breast cancer are more likely to share the results with other female family members, including children and their siblings, if they are aware of their relative’s opinion of genetic testing. These findings were recently published in the Journal of Family Psychology.
Fluctuation in Weight May Influence Risk for Ovarian Cancer
(04/11/2008)
A large study conducted in Austria reveals that large weight gains or losses may influence an individual’s risk for developing certain types of cancer, including ovarian cancer. Complete details of the study were published in the Annals of Oncology.
Combination of Biomarker Tests Highly Accurate in Detecting Ovarian Cancer
(02/20/2008)
A biomarker test that is still in clinical trials appears to be highly accurate in detecting ovarian cancer. These results were recently published in the journal Clinical Care Research.
Experience of Technician Affects Accuracy of Gynecologic Ultrasound in Ovarian Cancer Screening
(02/07/2008)
The expertise of the technician performing a gynecologic ultrasound not only affects the accuracy of the test results but also initial management of patients with suspected ovarian cancer. These results were recently published in The Lancet Oncology.
Oral Contraceptives Reduce Risk of Ovarian Cancer
(01/25/2008)
According to an article recently published in the Lancet, oral contraceptives reduce the long-term risk of ovarian cancer and have prevented approximately 100,000 deaths from ovarian cancer.
More...
Stage I
Ovarian Cancer National Alliance Announces Eleventh Annual Conference
(04/09/2008)
This year the Ovarian Cancer National Alliance will hold their eleventh annual conference, titled “Creating Currents of Change,” on Tuesday, July 8 through Thursday, July 10 at the Omni Shoreham Hotel in Washington, D.C.
Differences in IMRT Radiation Doses May Complicate Study Results in Gynecological Cancers
(03/31/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in gynecological cancers difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.
Specialty Hospitals Associated with Improved Survival in Early Ovarian Cancer
(03/18/2008)
Hospitals that specialize in care for ovarian cancer are associated with significantly improved survival for women with early ovarian cancer. These results were recently reported in the Journal of the National Cancer Institute.
Further Evidence in Favor of Care for Ovarian Cancer Patients by Gynecologic Oncologists
(01/21/2008)
According to an article recently published in Gynecologic Oncology, patients under 55 years of age with Stages IC–II ovarian cancer were more likely to receive chemotherapy if they received treatment from a gynecologic oncologist.
Aranesp® and Epoetin Alfa Do Not Increase Blood Clots in Ovarian Cancer
(05/01/2007)
According to an article recently published in Gynecologic Oncology, use of Aranesp® (darbepoetin alfa) or epoetin alfa (Procrit® or Epogen®) does not appear to increase the risk of developing medical complications due to blood clots in patients with ovarian or peritoneal (thin lining of the abdominal cavity) cancer who have chemotherapy-induced anemia.
More...
Stage II-IV
Ovarian Cancer National Alliance Announces Eleventh Annual Conference
(04/09/2008)
This year the Ovarian Cancer National Alliance will hold their eleventh annual conference, titled “Creating Currents of Change,” on Tuesday, July 8 through Thursday, July 10 at the Omni Shoreham Hotel in Washington, D.C.
Differences in IMRT Radiation Doses May Complicate Study Results in Gynecological Cancers
(03/31/2008)
Differences between the prescribed dose of radiation in intensity modulated radiation therapy (IMRT) and the dose that’s actually delivered may make comparison studies in gynecological cancers difficult to interpret. These findings were reported in the Journal of the National Cancer Institute.
Specialty Hospitals Associated with Improved Survival in Early Ovarian Cancer
(03/18/2008)
Hospitals that specialize in care for ovarian cancer are associated with significantly improved survival for women with early ovarian cancer. These results were recently reported in the Journal of the National Cancer Institute.
Statins at Time of Surgery May Improve Survival in Ovarian Cancer
(03/13/2008)
The use of statins at the time of surgery among women with ovarian cancer improved progression-free and overall survival among patients with ovarian cancer. These results were recently presented at the 2008 annual Society of Gynecologic Oncologists.
Further Evidence in Favor of Care for Ovarian Cancer Patients by Gynecologic Oncologists
(01/21/2008)
According to an article recently published in Gynecologic Oncology, patients under 55 years of age with Stages IC–II ovarian cancer were more likely to receive chemotherapy if they received treatment from a gynecologic oncologist.
More...
Recurrent
Ovarian Cancer National Alliance Announces Eleventh Annual Conference
(04/09/2008)
This year the Ovarian Cancer National Alliance will hold their eleventh annual conference, titled “Creating Currents of Change,” on Tuesday, July 8 through Thursday, July 10 at the Omni Shoreham Hotel in Washington, D.C.
Neulasta® on First Day of Chemotherapy May Be More Convenient for Gynecologic Cancers
(03/17/2008)
The administration of the blood cell growth factor Neulasta® (pegfilgrastim) on the first day of chemotherapy among women with gynecologic cancers may be as effective as and more convenient than second-day administration. These results were recently reported at the 2008 annual Society of Gynecologic Oncologists meeting.
Avastin® Effective for Recurrent Ovarian Cancer
(11/19/2007)
According to an article recently published in the Journal of Clinical Oncology, the targeted agent Avastin® (bevacizumab) appears to be effective and well tolerated for the treatment of recurrent ovarian cancer.
Avastin® May Provide Benefit in Recurrent Ovarian Cancer
(10/03/2007)
According to an article recently published in the International Journal of Gynecological Cancer, the targeted agent Avastin® (bevacizumab) plus chemotherapy may provide anticancer activity in patients with recurrent ovarian cancer.
Alvespimycin Benefits Patients with Heavily Pretreated HER2-positive Cancer
(09/12/2007)
Kosan Biosciences Incorporated reported results from an early-phase clinical trial indicating their targeted agent alvespimycin may provide clinical benefit to patients with human epidermal growth factor receptor 2 (HER2)-positive breast or ovarian cancers who have received extensive prior therapies.
More...